Case Study: Expanding AstraZeneca Mölndal Compound Management Capacity & Services to Support the New R&D Strategy
Or if you're already a Pharma IQ member, sign in below to download. Sign In to Watch Become a member to Watch
- Consolidating more work on the Mölndal site without overworking the Compound Management group
- Re-deploying automated systems and investing in supplementary tools
- First integration between an RTS high speed cherry picking and reformatting store and a BioCel
Max started working in the Compound Management group at AstraZeneca R&D Mölndal in 2000 and has since then been involved in numerous acquisitions and implementations of automated systems. After a two year long excursion into the land of physical quality of compounds he returned to compound management in the summer of 2007. Max currently holds a position as Associate Teamleader which involves responsibility for the compound management process in Mölndal along with its automation.